Application of pharmacogenomic strategies to the study of drug-induced birth defects
| Autor: | JS Leeder, Allen A. Mitchell |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Drug
Adult Heart Defects Congenital Pediatrics medicine.medical_specialty media_common.quotation_subject law.invention law Pregnancy medicine Humans Pharmacology (medical) media_common Pharmacology Individual susceptibility Clinical pharmacology business.industry Infant Newborn Abnormalities Drug-Induced Brain Congenital malformations Infant mortality Pharmacogenetics Pharmacogenomics Etiology Female business |
| Zdroj: | Clinical pharmacology and therapeutics. 81(4) |
| ISSN: | 0009-9236 |
| Popis: | Approximately 3% of all infants are born with one or more major birth defects, resulting in >150,000 affected babies each year in the US alone.1 At present, birth defects account for more than 21% of all infant deaths, making them the leading cause of infant mortality.2 Although the etiology and determinants of individual susceptibility are largely unknown for most congenital malformations, pharmacogenomic analyses offer promise for the future. Clinical Pharmacology & Therapeutics (2007) 81, 595–599. doi:10.1038/sj.clpt.6100128; published online 21 February 2007 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text